KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013, 3, 1–150.
Ekser, B.; Cooper, D.K.; Tector, A.J. The need for xenotransplantation as a source of organs and cells for clinical transplantation. Int J Surg 2015, 23, 199-204, doi:10.1016/j.ijsu.2015.06.066.
DOI: https://doi.org/10.1016/j.ijsu.2015.06.066
Ślubowska, K.; Durlik, M. Czynniki ryzyka sercowo-naczyniowego u biorców przeszczepu nerki. Forum Nefrol 2014, 7, 241–248
Hruby, Z. Nefrologia praktyczna; PZWL: Warszawa, 2001.
Szczeklik, A. Choroby wewnętrzne. Tom II; Medycyna praktyczna: Kraków, 2006.
Dębska-Ślizień, A.; Rutkowski, B.; Rutkowski, P.; Korejwo, G.; Gellert, R. Condition of renal replacement therapy in Poland-2016. 2018, 22, 1-8
Alsaad, K.O.; Herzenberg, A.M. Distinguishing diabetic nephropathy from other causes of glomerulosclerosis: an update. J Clin Pathol 2007, 60, 18-26, doi:10.1136/jcp.2005.035592.
DOI: https://doi.org/10.1136/jcp.2005.035592
Rodriguez-Iturbe, B.; Haas, M. Streptococcus pyogenes: Basic biology to clinical manifestations. Post-streptococcal glomerulonephritis; University of Oklahoma Health Sciences Center, Oklahoma City,: 2016.
Boils, C.L.; Nasr, S.H.; Walker, P.D.; Couser, W.G.; Larsen, C.P. Update on endocarditis-associated glomerulonephritis. Kidney Int 2015, 87, 1241-1249, doi:10.1038/ki.2014.424.
DOI: https://doi.org/10.1038/ki.2014.424
Molina, M.; Sánchez, J.; Sevillano, Á.; Bengoa, I.; Gutiérrez, E.; Martínez, M.A.; Hernández, E.; Praga, M. Two cases of glomerulonephritis in one patient infected with the hepatitis C virus. Nefrologia 2013, 33, 593-600, doi:10.3265/Nefrologia.pre2013.May.12067.
Zand, L.; Fervenza, F.C.; Nasr, S.H.; Sethi, S. Membranoproliferative glomerulonephritis associated with autoimmune diseases. J Nephrol 2014, 27, 165-171, doi:10.1007/s40620-014-0049-0.
DOI: https://doi.org/10.1007/s40620-014-0049-0
Liu, M.; Li, X.C.; Lu, L.; Cao, Y.; Sun, R.R.; Chen, S.; Zhang, P.Y. Cardiovascular disease and its relationship with chronic kidney disease. Eur Rev Med Pharmacol Sci 2014, 18, 2918-2926.
Ronco, C.; McCullough, P.; Anker, S.D.; Anand, I.; Aspromonte, N.; Bagshaw, S.M.; Bellomo, R.; Berl, T.; Bobek, I.; Cruz, D.N., et al. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J 2010, 31, 703-711, doi:10.1093/eurheartj/ehp507.
DOI: https://doi.org/10.1093/eurheartj/ehp507
Tonelli, M.; Wiebe, N.; Culleton, B.; House, A.; Rabbat, C.; Fok, M.; McAlister, F.; Garg, A.X. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006, 17, 2034-2047, doi:10.1681/asn.2005101085.
DOI: https://doi.org/10.1681/ASN.2005101085
Subbiah, A.K.; Chhabra, Y.K.; Mahajan, S. Cardiovascular disease in patients with chronic kidney disease: a neglected subgroup. Heart Asia 2016, 8, 56-61, doi:10.1136/heartasia-2016-010809.
DOI: https://doi.org/10.1136/heartasia-2016-010809
Manjunath, G.; Tighiouart, H.; Coresh, J.; Macleod, B.; Salem, D.N.; Griffith, J.L.; Levey, A.S.; Sarnak, M.J. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 2003, 63, 1121-1129, doi:10.1046/j.1523-1755.2003.00838.x.
DOI: https://doi.org/10.1046/j.1523-1755.2003.00838.x
Akchurin, O.M.; Kaskel, F. Update on inflammation in chronic kidney disease. Blood Purif 2015, 39, 84-92, doi:10.1159/000368940.
DOI: https://doi.org/10.1159/000368940
Reddy, Y.S.; Kiranmayi, V.S.; Bitla, A.R.; Krishna, G.S.; Rao, P.V.; Sivakumar, V. Nitric oxide status in patients with chronic kidney disease. Indian J Nephrol 2015, 25, 287-291, doi:10.4103/0971-4065.147376.
DOI: https://doi.org/10.4103/0971-4065.147376
De Gennaro Colonna, V.; Bianchi, M.; Pascale, V.; Ferrario, P.; Morelli, F.; Pascale, W.; Tomasoni, L.; Turiel, M. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule. Med Sci Monit 2009, 15, 91-101.
Förstermann, U.; Sessa, W.C. Nitric oxide synthases: regulation and function. Eur Heart J 2012, 33, 829-837, doi:10.1093/eurheartj/ehr304.
DOI: https://doi.org/10.1093/eurheartj/ehr304
Crichton, R.R.; Wilmet, S.; Legssyer, R.; Ward, R.J. Molecular and cellular mechanisms of iron homeostasis and toxicity in mammalian cells. J Inorg Biochem 2002, 91, 9-18, doi:10.1016/s0162-0134(02)00461-0.
DOI: https://doi.org/10.1016/S0162-0134(02)00461-0
Modi, G.K.; Naik, N. Atherosclerosis in chronic kidney disease: Striking while the Iron is labile. Indian J Nephrol 2013, 23, 337-339.
Cornelissen, A.; Guo, L.; Sakamoto, A.; Virmani, R.; Finn, A.V. New insights into the role of iron in inflammation and atherosclerosis. EBioMedicine 2019, 47, 598-606, doi:10.1016/j.ebiom.2019.08.014.
DOI: https://doi.org/10.1016/j.ebiom.2019.08.014
Palit, S.; Kendrick, J. Vascular calcification in chronic kidney disease: role of disordered mineral metabolism. Curr Pharm Des 2014, 20, 5829-5833.
DOI: https://doi.org/10.2174/1381612820666140212194926
Schlieper, G.; Schurgers, L.; Brandenburg, V.; Reutelingsperger, C.; Floege, J. Vascular calcification in chronic kidney disease: an update. Nephrol Dial Transplant 2016, 31, 31-39,doi:10.1093/ndt/gfv111.
DOI: https://doi.org/10.1093/ndt/gfv111
Sinnakirouchenan, R.; Holley, J.L. Peritoneal dialysis versus hemodialysis: risks, benefits, and access issues. Adv Chronic Kidney Dis 2011, 18, 428-432, doi:10.1053/j.ackd.2011.09.001.
DOI: https://doi.org/10.1053/j.ackd.2011.09.001
Yang, F.; Khin, L.W.; Lau, T.; Chua, H.R.; Vathsala, A.; Lee, E.; Luo, N. Hemodialysis versus Peritoneal Dialysis: A Comparison of Survival Outcomes in South-East Asian Patients with End-Stage Renal Disease. PLoS One 2015, 10, e0140195, doi:10.1371/journal.pone.0140195.
DOI: https://doi.org/10.1371/journal.pone.0140195
Weir, M.R.; Burgess, E.D.; Cooper, J.E.; Fenves, A.Z.; Goldsmith, D.; McKay, D.; Mehrotra, A.; Mitsnefes, M.M.; Sica, D.A.; Taler, S.J. Assessment and management of hypertension in transplant patients. J Am Soc Nephrol 2015, 26, 1248-1260, doi:10.1681/asn.2014080834.
DOI: https://doi.org/10.1681/ASN.2014080834
Kraus, M.A.; Kansal, S.; Copland, M.; Komenda, P.; Weinhandl, E.D.; Bakris, G.L.; Chan, C.T.; Fluck, R.J.; Burkart, J.M. Intensive Hemodialysis and Potential Risks With Increasing Treatment. Am J Kidney Dis 2016, 68, S51-S58, doi:10.1053/j.ajkd.2016.05.020.
DOI: https://doi.org/10.1053/j.ajkd.2016.05.020
Vikrant, S.; Guleria, R.C.; Kanga, A.; Verma, B.S.; Singh, D.; Dheer, S.K. Microbiological aspects of peritonitis in patients on continuous ambulatory peritoneal dialysis. Indian J Nephrol 2013, 23, 12-17, doi:10.4103/0971-4065.107188.
DOI: https://doi.org/10.4103/0971-4065.107188
O'Connor, N.R.; Kumar, P. Conservative Management of End-Stage Renal Disease without Dialysis: A Systematic Review. Journal of Palliative Medicine 2012, 15, 228-235, doi:10.1089/jpm.2011.0207.
DOI: https://doi.org/10.1089/jpm.2011.0207
Gętek, M.; Nowakowska- Zajdel, E. Quality of life of patients on dialysis and after renal transplantation. Ann Acad Med Siles 2010, 64, 23-30.
Biuletyn informacyjny. Centrum Organizacyjno - Koordynacyjne ds. Transplantacji "Poltransplant". 2018;1. www. poltransplant.pl/Download/Biuletyn_2018.pdf ( 21.08.2020).
Biuletyn informacyjny. Centrum Organizacyjno - Koordynacyjne ds. Transplantacji " Poltransplant ". 2020;1. www.poltransplant.pl/Download/Biuletyn2020.pdf (10.10.2020).
Gołąb, J.; Jakóbisiak, M.; Lasek, W.; Stokłosa, T. Immunologia; Towarzystwo Naukowe PWN: Warszawa, 2012.
Moreau, A.; Varey, E.; Anegon, I.; Cuturi, M.C. Effector mechanisms of rejection. Cold Spring Harb Perspect Med 2013, 3, a015461, doi:10.1101/cshperspect.a015461.
DOI: https://doi.org/10.1101/cshperspect.a015461
Bhatti, A.B.; Usman, M. Chronic Renal Transplant Rejection and Possible Anti-Proliferative Drug Targets. Cureus 2015, 7, e376, doi:10.7759/cureus.376.
DOI: https://doi.org/10.7759/cureus.376
Ghods, A.J. Living kidney donation: the outcomes for donors. Int J Organ Transplant Med 2010, 1, 63-71.
BTS/RA. Living Donor Kidney Transplantation Guidelines 2018 www.bts .org.uk.
KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors. Transplantation 2017, 101, 1–109.
Abramowicz, D.; Cochat, P.; Claas, F.H.; Heemann, U.; Pascual, J.; Dudley, C.; Harden, P.; Hourmant, M.; Maggiore, U.; Salvadori, M., et al. European Renal Best Practice Guideline on kidney donor and recipient evaluation and perioperative care. Nephrol Dial Transplant 2015, 30, 1790-1797, doi:10.1093/ndt/gfu216.
DOI: https://doi.org/10.1093/ndt/gfu216
Alelign, T.; Ahmed, M.M.; Bobosha, K.; Tadesse, Y.; Howe, R.; Petros, B. Kidney Transplantation: The Challenge of Human Leukocyte Antigen and Its Therapeutic Strategies. J Immunol Res 2018, 2018, 1-18, doi:10.1155/2018/5986740.
DOI: https://doi.org/10.1155/2018/5986740
Stoumpos, S.; Jardine, A.G.; Mark, P.B. Cardiovascular morbidity and mortality after kidney transplantation. Transpl Int 2015, 28, 10-21, doi:10.1111/tri.12413.
DOI: https://doi.org/10.1111/tri.12413
Durlik; M.; K., Z. Zalecenia dotyczące leczenia immunosupresyjnego po przeszczepieniu narządów unaczynionych. Fundacja Zjednoczeni dla Transplantacji: Warszawa 2016
KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009, Suppl 3, S1-155, doi:10.1111/j.1600-6143.2009.02834.x.
DOI: https://doi.org/10.1111/j.1600-6143.2009.02834.x
van Sandwijk, M.S.; Bemelman, F.J.; Ten Berge, I.J. Immunosuppressive drugs after solid organ transplantation. Neth J Med 2013, 71, 281-289.
Muntean, A.; Lucan, M. Immunosuppression in kidney transplantation. Clujul Med 2013, 86, 177-180.
Wagner, M.; Earley, A.K.; Webster, A.C.; Schmid, C.H.; Balk, E.M.; Uhlig, K. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 2015, CD007746, doi:10.1002/14651858.CD007746.pub2.
DOI: https://doi.org/10.1002/14651858.CD007746.pub2
Friedewald, J.J.; Reese, P.P. The kidney-first initiative: what is the current status of preemptive transplantation? Adv Chronic Kidney Dis 2012, 19, 252-256, doi:10.1053/j.ackd.2012.05.001.
DOI: https://doi.org/10.1053/j.ackd.2012.05.001
Rambod, M.; Shabani, M.; Shokrpour, N.; Rafii, F.; Mohammadalliha, J. Quality of life of hemodialysis and renal transplantation patients. Health Care Manag (Frederick) 2011, 30, 23-28, doi:10.1097/HCM.0b013e3182078ab6.
DOI: https://doi.org/10.1097/HCM.0b013e3182078ab6
Singh, S.K.; Cole, E.H.; Kim, S.J. Delayed Graft Function and Kidney Transplantation. In Kidney Transplantation, Weir, M., Lerma, E., Eds. Springer, New York, NY: Kidney Transplantation, 2014.
DOI: https://doi.org/10.1007/978-1-4939-0342-9_13
Florkowski, C.M.; Chew-Harris, J.S. Methods of Estimating GFR - Different Equations Including CKD-EPI. Clin Biochem Rev 2011, 32, 75-79.
Bartlomiejczyk, I.; Zochowska, D.; Sanko-Resmer, J.; Matuszewicz, D.; Paczek, L. Therapeutic monitoring of tacrolimus concentrations in blood of renal and liver transplant recipients: comparison of microparticle enzyme immunoassay and enzyme multiplied immunoassay methods. Transplant Proc 2006, 38, 94-96, doi:10.1016/j.transproceed.2005.12.042.
DOI: https://doi.org/10.1016/j.transproceed.2005.12.042
Mohammadpour, N.; Elyasi, S.; Vahdati, N.; Mohammadpour, A.H.; Shamsara, J. A review on therapeutic drug monitoring of immunosuppressant drugs. Iran J Basic Med Sci 2011, 14, 485-498.
Dasgupta, A.; Khalil, S.A.; Johnson-Davis, K.L. Analytical Performance Evaluation of a New Cobas Tacrolimus Assay on Cobas e411 Analyzer: Comparison of Values Obtained by the CMIA
Tacrolimus Assay and a Liquid Chromatography Combined with Tandem Mass Spectrometric Method. Ann Clin Lab Sci 2016, 46, 204-208.
Morgan, P.E.; Brown, N.W.; Tredger, J.M. A direct method for the measurement of everolimus and sirolimus in whole blood by LCMS/MS using an isotopic everolimus internal standard. Ther Drug Monit 2014, 36, 358-365, doi:10.1097/FTD.0000000000000006.
DOI: https://doi.org/10.1097/FTD.0000000000000006
Cravedi, P.; Heeger, P.S. Immunologic monitoring in transplantation revisited. Curr Opin Organ Transplant 2012, 17, 26-32, doi:10.1097/MOT.0b013e32834ee402.
DOI: https://doi.org/10.1097/MOT.0b013e32834ee402
Townamchai, N.; Safa, K.; Chandraker, A. Immunologic monitoring in kidney transplant recipients. Kidney Res Clin Pract 2013, 32, 52-61, doi:10.1016/j.krcp.2013.04.002.
DOI: https://doi.org/10.1016/j.krcp.2013.04.002
Bojanowska, M.; Białobrzeska, B. Native and transplanted kidney biopsy — holistic nursing care. Forum Nefrol 2010, 3, 317–325
Sawosz, M.; Bączkowska, T. Protocol biopsies of a transplanted kidney. 2012, 5 105–109
Tapia-Canelas, C.; Zometa, R.; López-Oliva, M.O.; Jiménez, C.; Rivas, B.; Escuin, F.; Yébenes, L.; Selgas, R. Complications associated with renal graft biopsy in transplant patients. Nefrologia 2014, 34, 115-119, doi:10.3265/Nefrologia.pre2013.Nov.12232.
Rao, N.N.; Coates, P.T. Cardiovascular Disease After Kidney Transplant. Semin Nephrol 2018, 38, 291-297, doi:10.1016/j.semnephrol.2018.02.008.
DOI: https://doi.org/10.1016/j.semnephrol.2018.02.008
Alani, H.; Tamimi, A.; Tamimi, N. Cardiovascular co-morbidity in chronic kidney disease: Current knowledge and future research needs. World J Nephrol 2014, 3, 156-168, doi:10.5527/wjn.v3.i4.156.
DOI: https://doi.org/10.5527/wjn.v3.i4.156
Dosi, R.; Bhatt, N.; Shah, P.; Patell, R. Cardiovascular disease and menopause. J Clin Diagn Res 2014, 8, 62-64, doi:10.7860/JCDR/2014/6457.4009.
DOI: https://doi.org/10.7860/JCDR/2014/6457.4009
Kolber, M.R.; Scrimshaw, C. Family history of cardiovascular disease. Can Fam Physician 2014, 60, 1016.
Muntner, P.; He, J.; Astor, B.C.; Folsom, A.R.; Coresh, J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol 2005, 16, 529-538, doi:10.1681/ASN.2004080656.
DOI: https://doi.org/10.1681/ASN.2004080656
Vlagopoulos, P.T.; Sarnak, M.J. Traditional and nontraditional cardiovascular risk factors in chronic kidney disease. Med Clin North Am 2005, 89, 587-611, doi:10.1016/j.mcna.2004.11.003.
DOI: https://doi.org/10.1016/j.mcna.2004.11.003
Romero, J.R.; Morris, J.; Pikula, A. Stroke prevention: modifying risk factors. Therapeutic advances in cardiovascular disease 2008, 2, 287-303, doi:10.1177/1753944708093847.
DOI: https://doi.org/10.1177/1753944708093847
Collins, P. Risk factors for cardiovascular disease and hormone therapy in women. Heart 2006, 92 Suppl 3, iii24-28, doi:10.1136/hrt.2005.071787.
DOI: https://doi.org/10.1136/hrt.2005.071787
Lewington, S.; Clarke, R.; Qizilbash, N.; Peto, R.; Collins, R.; Collaboration, P.S. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360, 1903-1913.
DOI: https://doi.org/10.1016/S0140-6736(02)11911-8
Aronow, W.S. Treatment of systemic hypertension. Am J Cardiovasc Dis 2012, 2, 160-170.
Schnohr, P.; Lange, P.; Scharling, H.; Jensen, J.S. Long-term physical activity in leisure time and mortality from coronary heart disease, stroke, respiratory diseases, and cancer. The Copenhagen City Heart Study. Eur J Cardiovasc Prev Rehabil 2006, 13, 173-179, doi:10.1097/01.hjr.0000198923.80555.b7.
DOI: https://doi.org/10.1097/01.hjr.0000198923.80555.b7
Hap, K.; Madziarska, K.; Hap, W.; Mazanowska, O. Phenotypic risk factors for new-onset diabetes mellitus (NODAT) in renal transplant recipients. Postepy Hig Med Dosw (Online) 2014, 68, 1347-1351, doi:10.5604/17322693.1129186.
DOI: https://doi.org/10.5604/17322693.1129186
Murchison, L.E. Hyperlipidaemia. Br Med J (Clin Res Ed) 1985, 290, 535-538.
DOI: https://doi.org/10.1136/bmj.290.6467.535
Nelson, R.H. Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care 2013, 40, 195-211, doi:10.1016/j.pop.2012.11.003.
DOI: https://doi.org/10.1016/j.pop.2012.11.003
Rafieian-Kopaei, M.; Setorki, M.; Doudi, M.; Baradaran, A.; Nasri, H. Atherosclerosis: process, indicators, risk factors and new hopes. Int J Prev Med 2014, 5, 927-946.
Fischer, S.; Schatz, U.; Julius, U. Practical recommendations for the management of hyperlipidemia. Atheroscler Suppl 2015, 18, 194-198, doi:10.1016/j.atherosclerosissup.2015.02.029.
DOI: https://doi.org/10.1016/j.atherosclerosissup.2015.02.029
Messner, B.; Bernhard, D. Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler Thromb Vasc Biol 2014, 34, 509-515, doi:10.1161/ATVBAHA.113.300156.
DOI: https://doi.org/10.1161/ATVBAHA.113.300156
Yusuf, S.; Hawken, S.; Ounpuu, S.; Dans, T.; Avezum, A.; Lanas, F.; McQueen, M.; Budaj, A.; Pais, P.; Varigos, J., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364, 937-952, doi:10.1016/S0140-6736(04)17018-9.
DOI: https://doi.org/10.1016/S0140-6736(04)17018-9
Neale, J.; Smith, A.C. Cardiovascular risk factors following renal transplant. World J Transplant 2015, 5, 183-195, doi:10.5500/wjt.v5.i4.183.
DOI: https://doi.org/10.5500/wjt.v5.i4.183
Kokkinos, P. Physical activity, health benefits, and mortality risk. ISRN Cardiol 2012, 2012, 718789, doi:10.5402/2012/718789.
DOI: https://doi.org/10.5402/2012/718789
Klop, B.; Elte, J.W.; Cabezas, M.C. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients 2013, 5, 1218-1240, doi:10.3390/nu5041218.
DOI: https://doi.org/10.3390/nu5041218
Kubota, Y.; Evenson, K.R.; MacLehose, R.F.; Roetker, N.S.; Joshu, C.E.; Folsom, A.R. Physical Activity and Lifetime Risk of Cardiovascular Disease and Cancer. Med Sci Sports Exerc 2017, 8, 1599–1605, doi:10.1249/MSS.0000000000001274.
DOI: https://doi.org/10.1249/MSS.0000000000001274
Romano, G.; Lorenzon, E.; Montanaro, D. Effects of exercise in renal transplant recipients. World J Transplant 2012, 2, 46-50, doi:10.5500/wjt.v2.i4.46.
DOI: https://doi.org/10.5500/wjt.v2.i4.46
Orlandi, G.; Sofi, F.; Moscarelli, L.; Cirami, L.; Mancini, S.; Stefani, L. Exercise Prescription in Renal Transplant Recipients: From Sports Medicine Toward Multidisciplinary Aspects: A Pilot Study. J. Funct. Morphol. Kinesiol. 2020, 5, 10, doi:https://doi.org/10.3390/jfmk5010010.
DOI: https://doi.org/10.3390/jfmk5010010
Ferguson, B. ACSM’s Guidelines for Exercise Testing and Prescription 9th Ed. 2014. The Journal of the Canadian Chiropractic Association 2014, 58, 328-328.
Małgorzewicz, S.; Ciechanowski, K.; Kozłowska, L.; Krzanowska, K.; Krzanowski, M.; Kaczkan, M.; Borek, P.; Jankowska, M.; Rutkowski, B.; Dębska-Ślizień, A. Nutrition recommendations in chronic kidney disease - the position of the working group of the Polish Nephrological Society. Forum Nefrologiczne 2019, 12, 240–278.
Currie, G.; Delles, C. Proteinuria and its relation to cardiovascular disease. Int J Nephrol Renovasc Dis 2013, 7, 13-24, doi:10.2147/IJNRD.S40522.
DOI: https://doi.org/10.2147/IJNRD.S40522
Hillege, H.L.; Fidler, V.; Diercks, G.F.; van Gilst, W.H.; de Zeeuw, D.; van Veldhuisen, D.J.; Gans, R.O.; Janssen, W.M.; Grobbee, D.E.; de Jong, P.E., et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002, 106, 1777-1782, doi:10.1161/01.cir.0000031732.78052.81.
DOI: https://doi.org/10.1161/01.CIR.0000031732.78052.81
Lee, W.H.; Hsu, P.C.; Chu, C.Y.; Lee, H.H.; Lee, M.K.; Lee, C.S.; Yen, H.W.; Lin, T.H.; Voon, W.C.; Lai, W.T., et al. Anemia as an Independent Predictor of Adverse Cardiac Outcomes in Patients with Atrial Fibrillation. Int J Med Sci 2015, 12, 618-624, doi:10.7150/ijms.11924.
DOI: https://doi.org/10.7150/ijms.11924
Durlik, M. Patogeneza i klinika niedokrwistości u chorych po przeszczepieniu nerki. Forum Nefrol. 2010, 3, 298-304
Karthikeyan, V.; Karpinski, J.; Nair, R.C.; Knoll, G. The burden of chronic kidney disease in renal transplant recipients. Am J Transplant 2004, 4, 262-269.
DOI: https://doi.org/10.1046/j.1600-6143.2003.00315.x
Hariharan, S. Recommendations for outpatient monitoring of kidney transplant recipients. Am J Kidney Dis 2006, 47, S22-36, doi:10.1053/j.ajkd.2005.12.046.
DOI: https://doi.org/10.1053/j.ajkd.2005.12.046
Sarnak, M.J.; Tighiouart, H.; Manjunath, G.; MacLeod, B.; Griffith, J.; Salem, D.; Levey, A.S. Anemia as a risk factor for cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study. J Am Coll Cardiol 2002, 40, 27-33.
DOI: https://doi.org/10.1016/S0735-1097(02)01938-1
Cervantes Gracia, K.; Llanas-Cornejo, D.; Husi, H. CVD and Oxidative Stress. J Clin Med 2017, 6, 22, doi:10.3390/jcm6020022.
DOI: https://doi.org/10.3390/jcm6020022
Tabriziani, H.; Lipkowitz, M.S.; Vuong, N. Chronic kidney disease, kidney transplantation and oxidative stress: a new look to successful kidney transplantation. Clin Kidney J 2018, 11, 130-135, doi:10.1093/ckj/sfx091.
DOI: https://doi.org/10.1093/ckj/sfx091
Sezer, S.; Akcay, A.; Ozdemir, F.N.; Kulah, E.; Arat, Z.; Haberal, M. Post-transplant C-reactive protein monitoring can predict chronic allograft nephropathy. Clin Transplant 2004, 18, 722-725, doi:10.1111/j.1399-0012.2004.00286.x.
DOI: https://doi.org/10.1111/j.1399-0012.2004.00286.x
Kaptoge, S.; White, I.R.; Thompson, S.G.; Wood, A.M.; Lewington, S.; Lowe, G.D.; Danesh, J.; Collaboration, F.S. Associations of plasma fibrinogen levels with established cardiovascular disease risk factors, inflammatory markers, and other characteristics: individual participant meta-analysis of 154,211 adults in 31 prospective studies: the fibrinogen studies collaboration. Am J Epidemiol 2007, 166, 867-879, doi:10.1093/aje/kwm191.
DOI: https://doi.org/10.1093/aje/kwm191
Ozdemir, N.F.; Elsurer, R.; Ibis, A.; Arat, Z.; Haberal, M. Serum Creactive protein surge in renal transplant recipients: link with allograft survival. Transplant Proc 2007, 39, 934-937, doi:10.1016/j.transproceed.2007.02.023.
DOI: https://doi.org/10.1016/j.transproceed.2007.02.023
Vanholder, R.C.; Eloot, S.; Glorieux, G.L. Future Avenues to Decrease Uremic Toxin Concentration. Am J Kidney Dis 2016, 67, 664-676, doi:10.1053/j.ajkd.2015.08.029.
DOI: https://doi.org/10.1053/j.ajkd.2015.08.029
Vanholder, R.; Van Laecke, S.; Glorieux, G. What is new in uremic toxicity? Pediatr Nephrol 2008, 23, 1211-1221, doi:10.1007/s00467-008-0762-9.
DOI: https://doi.org/10.1007/s00467-008-0762-9
Barreto, F.C.; Stinghen, A.E.; de Oliveira, R.B.; Franco, A.T.; Moreno, A.N.; Barreto, D.V.; Pecoits-Filho, R.; Drüeke, T.B.; Massy, Z.A. The quest for a better understanding of chronic kidney disease complications: an update on uremic toxins. J Bras Nefrol 2014, 36, 221-235.
DOI: https://doi.org/10.5935/0101-2800.20140033
Cha, R.H.; Kang, S.W.; Park, C.W.; Cha, D.R.; Na, K.Y.; Kim, S.G.; Yoon, S.A.; Han, S.Y.; Chang, J.H.; Park, S.K., et al. A Randomized, Controlled Trial of Oral Intestinal Sorbent AST-120 on Renal Function Deterioration in Patients with Advanced Renal Dysfunction. Clin J Am Soc Nephrol 2016, 11, 559-567, doi:10.2215/CJN.12011214.
DOI: https://doi.org/10.2215/CJN.12011214
Aldámiz-Echevarría, L.; Andrade, F. Asymmetric dimethylarginine, endothelial dysfunction and renal disease. Int J Mol Sci 2012, 13, 11288-11311, doi:10.3390/ijms130911288.
DOI: https://doi.org/10.3390/ijms130911288
Valkonen, V.P.; Päivä, H.; Salonen, J.T.; Lakka, T.A.; Lehtimäki, T.; Laakso, J.; Laaksonen, R. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001, 358, 2127-2128, doi:10.1016/S0140-6736(01)07184-7.
DOI: https://doi.org/10.1016/S0140-6736(01)07184-7
Willeit, P.; Freitag, D.F.; Laukkanen, J.A.; Chowdhury, S.; Gobin, R.; Mayr, M.; Di Angelantonio, E.; Chowdhury, R. Asymmetric dimethylarginine and cardiovascular risk: systematic review and meta-analysis of 22 prospective studies. J Am Heart Assoc 2015, 4, e001833, doi:10.1161/JAHA.115.001833.
DOI: https://doi.org/10.1161/JAHA.115.001833
Zoccali, C.; Bode-Böger, S.; Mallamaci, F.; Benedetto, F.; Tripepi, G.; Malatino, L.; Cataliotti, A.; Bellanuova, I.; Fermo, I.; Frölich, J., et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001, 358, 2113-2117.
DOI: https://doi.org/10.1016/S0140-6736(01)07217-8
Ravani, P.; Tripepi, G.; Malberti, F.; Testa, S.; Mallamaci, F.; Zoccali, C. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 2005, 16, 2449-2455, doi:10.1681/ASN.2005010076.
DOI: https://doi.org/10.1681/ASN.2005010076
Lau, W.L.; Vaziri, N.D. Urea, a true uremic toxin: the empire strikes back. Clin Sci (Lond) 2017, 131, 3-12, doi:10.1042/CS20160203.
DOI: https://doi.org/10.1042/CS20160203
Ndrepepa, G. Uric acid and cardiovascular disease. Clin Chim Acta 2018, 484, 150-163, doi:10.1016/j.cca.2018.05.046.
DOI: https://doi.org/10.1016/j.cca.2018.05.046
Currò, M.; Gugliandolo, A.; Gangemi, C.; Risitano, R.; Ientile, R.; Caccamo, D. Toxic effects of mildly elevated homocysteine concentrations in neuronal-like cells. Neurochem Res 2014, 39, 1485-1495, doi:10.1007/s11064-014-1338-7.
DOI: https://doi.org/10.1007/s11064-014-1338-7
Ye, Z.; Zhang, Q.; Li, Y.; Wang, C.; Zhang, J.; Ma, X.; Peng, H.; Lou, T. High Prevalence of Hyperhomocysteinemia and Its Association with Target Organ Damage in Chinese Patients with Chronic Kidney Disease. Nutrients 2016, 8, 645, doi:10.3390/nu8100645.
DOI: https://doi.org/10.3390/nu8100645
Baszczuk, A.; Kopczyński, Z. Hyperhomocysteinemia in patients with cardiovascular disease. Postepy Hig Med Dosw (Online) 2014, 68, 579-589, doi:10.5604/17322693.1102340.
DOI: https://doi.org/10.5604/17322693.1102340
Ganguly, P.; Alam, S.F. Role of homocysteine in the development of cardiovascular disease. Nutr J 2015, 14, 6, doi:10.1186/1475-2891-14-6.
DOI: https://doi.org/10.1186/1475-2891-14-6
van Ballegooijen, A.J.; Reinders, I.; Visser, M.; Brouwer, I.A. Parathyroid hormone and cardiovascular disease events: A systematic review and meta-analysis of prospective studies. Am Heart J 2013, 165, 655-664, 664.e651-655, doi:10.1016/j.ahj.2013.02.014.
DOI: https://doi.org/10.1016/j.ahj.2013.02.014
Goettsch, C.; Iwata, H.; Aikawa, E. Parathyroid hormone: critical bridge between bone metabolism and cardiovascular disease. Arterioscler Thromb Vasc Biol 2014, 34, 1333-1335, doi:10.1161/ATVBAHA.114.303637.
DOI: https://doi.org/10.1161/ATVBAHA.114.303637
Korytowska, N.; Wyczałkowska-Tomasik, A.; Wiśniewska, A.; Pączek, L.; Giebułtowicz, J. Development of the LC-MS/MS method for determining the p-cresol level in plasma. J Pharm Biomed Anal 2019, 167, 149-154, doi:10.1016/j.jpba.2019.01.041.
DOI: https://doi.org/10.1016/j.jpba.2019.01.041
Leong, S.C.; Sirich, T.L. Indoxyl Sulfate-Review of Toxicity and Therapeutic Strategies. Toxins (Basel) 2016, 8, 358, doi:10.3390/toxins8120358.
DOI: https://doi.org/10.3390/toxins8120358
Gryp, T.; Vanholder, R.; Vaneechoutte, M.; Glorieux, G. p-Cresyl Sulfate. Toxins (Basel) 2017, 9, 52, doi:10.3390/toxins9020052.
DOI: https://doi.org/10.3390/toxins9020052
Korytowska, N.; Sankowski, B.; Wyczałkowska-Tomasik, A.; Pączek, L.; Wroczyński, P.; Giebułtowicz, J. The utility of saliva testing in the estimation of uremic toxin levels in serum. Clin Chem Lab Med 2018, 57, 230-237, doi:10.1515/cclm-2018-0087.
DOI: https://doi.org/10.1515/cclm-2018-0087
Chiu, C.A.; Lu, L.F.; Yu, T.H.; Hung, W.C.; Chung, F.M.; Tsai, I.T.; Yang, C.Y.; Hsu, C.C.; Lu, Y.C.; Wang, C.P., et al. Increased levels of total P-Cresylsulphate and indoxyl sulphate are associated with coronary artery disease in patients with diabetic nephropathy. Rev Diabet Stud 2010, 7, 275-284, doi:10.1900/RDS.2010.7.275.
DOI: https://doi.org/10.1900/RDS.2010.7.275
Wang, Z.; Klipfell, E.; Bennett, B.J.; Koeth, R.; Levison, B.S.; DuGar, B.; Feldstein, A.E.; Britt, E.B.; Fu, X.; Chung, Y.-M., et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011, 472, 57-63, doi:10.1038/nature09922.
DOI: https://doi.org/10.1038/nature09922
Tang, W.H.; Wang, Z.; Kennedy, D.J.; Wu, Y.; Buffa, J.A.; AgatisaBoyle, B.; Li, X.S.; Levison, B.S.; Hazen, S.L. Gut microbiotadependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res 2015, 116, 448-455, doi:10.1161/CIRCRESAHA.116.305360.
DOI: https://doi.org/10.1161/CIRCRESAHA.116.305360
Chou, R.-H.; Chen, C.-Y.; Chen, I.C.; Huang, H.-L.; Lu, Y.-W.; Kuo, C.-S.; Chang, C.-C.; Huang, P.-H.; Chen, J.-W.; Lin, S.-J. Trimethylamine N-Oxide, Circulating Endothelial Progenitor Cells, and Endothelial Function in Patients with Stable Angina. Scientific Reports 2019, 9, 4249, doi:10.1038/s41598-019-40638-y.
DOI: https://doi.org/10.1038/s41598-019-40638-y
English
Język Polski
